Treatment algorithms featured in Brain Trauma Foundation’s update of guidelines for care of patients with penetrating traumatic brain injury
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 04:16 ET (22-Jun-2026 08:16 GMT/UTC)
Cambridge, MA, February 17, 2025 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies. The initiative builds on MSK’s global leadership in this field under the direction of Yelena Y. Janjigian, MD, Carroll and Milton Petrie Chair; Chief, GI Oncology; and Founding Director of the MSK GEC Therapeutics Accelerator, whose group has delivered multiple practice-changing advances in gastric and gastroesophageal junction cancers. Patrick Evans, BS, MBA, Senior Project Manager in the Janjigian Lab, will serve as the MSK project lead, supporting integration of scientific, operational, and translational efforts across teams.
MIT chemical engineers used AI to optimize the selection of codon sequences for protein drugs produced by yeast, which could reduce the costs of developing and manufacturing these drugs.